Study to Compare Efficacy and Safety of LUBT010 and Lucentis in Patients With Neovascular AMD

  • STATUS
    Recruiting
  • End date
    Oct 15, 2022
  • participants needed
    600
  • sponsor
    Lupin Ltd.
Updated on 15 March 2021

Summary

This study is designed to compare the efficacy, safety and immunogenicity of LUBT010 with Lucentis given as once monthly intravitreal injection in patients with neovascular age-related macular degeneration (AMD).

Description

This is a global, phase III, double blind, randomized controlled study to compare the efficacy, safety & immunogenicity of LUBT010 with Lucentis in patients with neovascular age-related macular degeneration.

Eligible patients will be randomly assigned in 1:1 ratio to receive once monthly intravitreal injection of LUBT010 or Lucentis for 12 months.

Details
Condition Neovascular Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Neovascular Age Related Macular Degeneration
Treatment Lucentis (ranibizumab), LUBT010 (proposed ranibizumab biosimilar)
Clinical Study IdentifierNCT04690556
SponsorLupin Ltd.
Last Modified on15 March 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Ambulatory male or female participants with age 50 years at the time of screening
Capable of understanding and giving written informed consent
Primary or recurrent (anti-VEGF nave) active CNV lesions involving the foveal center secondary to AMD
BCVA between 20/40 and 20/200 (Snellen equivalent) in the study eye, using ETDRS testing
Willingness and ability to undertake all scheduled visits and assessments

Exclusion Criteria

Known hypersensitivity to ranibizumab or any of the components of study medication
Known history of allergy to fluorescein dye
Scar, fibrosis, or atrophy involving the center of the fovea in the study eye
Subretinal hemorrhage in the study eye that involves the center of the fovea
Uncontrolled glaucoma
Use of prohibited treatments
Other In-/Exclusion criteria may apply
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note